Year: 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is designed to selectively inhibit APRIL, a key driver of pathogenic IgA production in IgAN, a progressive autoimmune disease that frequently leads to end-stage kidney disease over a patient’s lifetime. Jade has engineered JADE101 with properties intended to capture the full efficacy of APRIL pathway inhibition while enabling patient-friendly...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients undergoing total knee replacement initiated as part of broad factor XI program evaluating the two antibodies across a range of patient populations and clinical settings Regeneron to host virtual ‘Regeneron Roundtable’ investor event to discuss its factor XI development program on Monday, November 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov. 08, 2025...

– Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Month 42 (p=0.045) in ATTR-CM participants with the genetic variant p.Val142Ile (V142I, V122I) compared to patients initially randomized to placebo in the ATTRibute-CM study– This is the first report of clinical benefit of this magnitude observed in this high-risk population with significant unmet need PALO ALTO, Calif., Nov. 08, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new...

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose- -Among participants with elevated baseline TG (>150 mg/dL), a mean reduction of 60% in TG were observed at therapeutic doses- -CTX310 was well tolerated with no treatment-related serious adverse events and no ≥Grade 3 changes in liver transaminases- -Findings simultaneously published in The New England Journal of Medicine entitled “First-in-Human Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3”-ZUG,...

Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera.  On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) which was declared superior by Metsera’s board of directors.   On 4 November 2025, Novo Nordisk confirmed that it had submitted an updated unsolicited proposal to acquire Metsera price of 62.20 USD per share in cash (equal to an approximate aggregated equity value of 7.2 billion USD or approximate enterprise value of 6.7 billion USD) and contingent value rights (CVRs) for up to 24.00 USD per share in cash (or an approximate aggregated value of up to 2.8 billion USD) based on the achievement of certain clinical and regulatory milestones which was declared superior by Metsera’s board of...

XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was recognized with the “Social Responsibility Golden Bull Award” at the 2025 Xiamen Industry Development Conference and Listed Companies (Hong Kong) Golden Bull Awards Ceremony, organized by China Securities Journal. The conference brought together corporate leaders and investors to discuss how Hong Kong-listed enterprises can leverage innovation and governance to achieve sustainable global growth. This year marked the inaugural edition of the Golden Bull Awards for Hong Kong-listed companies.Fangzhou was recognized with the “Social Responsibility Golden Bull Award” Fangzhou distinguished itself among the field of Hong Kong-listed companies to receive the honor,...

CALGARY, Alberta, Nov. 07, 2025 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Company”) announces that it has been notified of the decision issued in the domestic arbitration proceedings initiated by VP Ingenergía S.A.S. E.S.P. before the Arbitration and Conciliation Center of the Bogotá Chamber of Commerce. The arbitration addressed the termination of three natural gas supply contracts, which were terminated by Canacol due to VP Ingenergía’s contractual breaches, including the failure to provide the contractually required guarantees and the failure to pay for gas delivered. During the proceedings, the relationship between these facts and the occurrence of a force majeure event experienced by Canacol in 2023 was also examined. The arbitral tribunal decided to accept Canacol’s arguments regarding the invalidity of the...

VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSXV: AOT.H; OTCQB: AOTVF) (“Ascot” or the “Company”) announces it is undertaking a rights offering to raise gross proceeds of up to C$14,871,517 (the “Rights Offering”). Rights Offering Pursuant to the Rights Offering, the Company will be offering 1,487,151,720 rights (the “Rights”) to certain holders (the “Shareholders”) of common shares in the capital of Ascot (the “Common Shares”) at the close of business on the record date of November 18, 2025 (the “Record Date”) on the basis of one (1) Right for each Common Share held. Each one (1) Right will entitle the holder to subscribe for one (1) Common Share of the Company (a “Rights Share”) at the subscription price of C$0.01 per Rights Share (the “Basic Subscription Privilege”). The Common Shares...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — South Star Battery Metals Corp. (“South Star” or the “Company”) (TSXV: STS) (OTCQB: STSBF) is pleased to announce that, due to significant market demand, the Company has increased the size of its previously announced non-brokered private placement (the “Offering”) of units (the “Units”) from C$6,255,000 to up to C$6,672,000 (US$4,800,000). The upsized Offering will now consist of up to 44,480,000 Units at a price of C$0.15 per Unit. Each Unit consists of one common share (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one additional Share at a price of C$0.20 per Share for a period of five (5) years from the applicable...